reason report
strong qtr skyrizi humira margin expans ahead
bottom line last friday impress investor
robust sale key new establish product skyrizi beat
consensu us humira consensu
well bullish initi guidanc total sale reach
increas qoq yoy non-gaap ep
increas yoy decreas sequenti
increas revenu forecast next year mainli reflect
stronger growth expect skyrizi rinvoq humira sale
us provid initi ex-allergan guidanc top-line
non-gaap ep guidanc exceed consensu estim
manag continu expect allergan acquisit close
quarter re-affirmed current dividend pay-out polici growth
outlook least provid usual
inform disclosur earli mid late stage pipelin
call nevertheless import pipelin mileston
mainli new indic exist late stage medicin skyrizi
rinvoq veliparib venclexta result pivot
trial regulatori review guarante much less riski
event true nme new drug class expect abbvi
continu trade posit strength exist
immunolog oncolog asset expand indic
well prospect rapid integr allergan
acquisit close later quarter opportun view
re-pric compani stock least top rang
larg biotech compani rang peer diversifi
increas revenu forecast base stronger skyrizi/
rinvoq uptak slower humira eros price target increas
reiter op base latest sale trend manag
commentari disclosur increas revenu forecast
mostli driven higher forecast
humira skyrizi
rinvoq
increas revenu forecast recent consensu
updat oper expens estim lower
benefit lower sg estim partial off-set higher
cog oper margin forecast bp higher
bp higher combin non-gaap ep estim
increas nearli in-lin consensu
higher base chang
averag dcf price-to-earnings p/sale
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm dilut ep includ option expens present
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
estim revenu cash flow ep chang peer compani
multipl increas price target reiter
outperform rate abbv stock expect stock continu
trade strongli posit revis close larg transact
combin compani financi guidanc signific label-expand
trial result skyrizi rinvoq imbruvica venclexta
price target per share stock rate outperform
establish independ pharmaceut compani transit new
phase term scale oper effici plan acquisit allergan earli
allergan bring new revenu market categori outsid
current product portfolio allergan esthet busi one endur franchis
industri unlik advers affect mani risk face tradit
necessarili fan consolid sake see bring
disciplin decis allergan portfolio confid maxim
valu allergan esthet busi cash flow without disrupt effect
busi unit innov cultur commerci effect ad allergan dilut
abbvi exposur humira posit offer compani
signific opportun oper effici synergi alreadi
disclos face mani risk humira franchis rebat reform patent challeng
biosimilar pathway chang patent reform product cash flow seem
rel secur risk seem price investor expect beyond two
cornerston hematolog busi grow strongli sever year least
emerg combin neurosci portfolio gener signific revenu posit
cash flow earli import pipelin program combin compani
come skyrizi venclexta imbruvica new indic signific
increment opportun probabl allergan neurolog migrain psychiatri
schizophrenia program boost back indic compani
long sinc abandon see combin compani deliv mid-singl digit revenu growth
high singl digit ep growth offer investor attract low double-digit
sale sequenti yoy in-lin consensu
global humira sale flat q/q y/i beat forecast in-lin
consensu ou sale continu declin q/q y/i due biosimilar eros
ex-u market manag suggest earli us biosimilar eros like
steeper current estim initi year like flatten afterward
expect us humira continu grow
skyrizi sale exceed expect beat consensu estim nearli
skyrizi perform continu bullish trend sale increas significantli
beat consensu estim respect beat driven fast
adopt new switch patient in-play patient share reach compar last
quarter
rinvoq slightli consensu larg due on-going transit launch earli
access reimburs program rinvoq sale lower consensu
estim actual sale appear much lower script volum
manag indic due larg number patient still bridg earli
access program suggest would see signific acceler report sale
commerci access achiev rinvoq captur in-play rheumatoid
arthriti ra patient
report global imbruvica revenu grow y/i sequenti
higher consensu estim driven continu uptak first-lin
sequenti growth beat consensu miss estim
abbvi hcv revenu quarter viekira mavyret declin sequenti
us ex-u hcv under-perform report sale
consensu lower estim abbvi orilissa ramp still slower
expect report sale miss consensu estim
non-gaap ep in-lin consensu estim
total non-gaap expens in-lin consensu higher estim
report gross margin larg in-lin consensu estim
abbvi non-gaap sg expens flat compar consensu
estim expens consensu lower
estim report lower oper margin compar estim
in-lin consensu tax rate slightli lower consensu
estim
ex-allergan revenu ep guidanc exceed consensu
provid limit initi ex-allergan guidanc top-line non-gaap ep
exceed consensu estim expect top-line revenu achiev
growth compar consensu forecast non-gaap
guidanc also materi consensu estim
provid combin compani guidanc follow closur allergan
acquisit quarter
disclosur pipelin develop late stage catalyst like valu
driver
provid usual inform disclosur earli mid late
stage pipelin call signific new announc regard updat
timelin number late stage catalyst indic growth-driv approv
product potenti impact event includ skyrizi phase studi readout crohn
diseas cd psoriat arthriti second half year rinvoq phase studi
result atop dermat ad mid year regulatori submiss rinvoq psoriat
arthriti ankylos spondyl second half regulatori
submiss veliparib treatment ovarian cancer brca posit breast
cancer first half year exhibit
addit provid detail newli ad go add
clinic program includ earli stage studi oncolog program
immunolog program late stage studi venclexta acut myeloid leukemia
myelodysplast syndrom multipl myeloma mutat second phase
compani also increas emphasi bispecif program phase
psma bcma well highlight hand clinic develop program
neurosci prepar report earli stage data novel product
product immunolog includ phase readout tnf/steroid
treatment ra phase result jak/btk ra phase data
ravagalimab uc phase data roryt psoriasi two
novel candid oncolog teliso-v cmet phase data solid tumor abbv-
bcl-xli solid tumor
exhibit import clinical/regulatori event
new programsremov programsvenclexta solid prostat cancerempl mm scar-t heme tumorrova-t sclc solid tylamac filari diseasesvenclexta aml previous receiv stem cell tran venclexta mdsvenclexta phase studi mm mutationsphas phase ii phase abbvi inc
revenu forecast increas strong skyrizi/rinvoq outlook durabl us humira
base latest sale trend manag commentari disclosur increas
revenu forecast mostli driven higher forecast
humira skyrizi
rinvoq increas revenu forecast
recent consensu updat oper expens estim lower
benefit lower sg estim partial off-set higher cog oper
margin forecast bp higher bp higher combin
non-gaap ep estim increas nearli in-lin
consensu higher base chang estim
revenu cash flow ep chang peer compani multipl increas
price target reiter outperform rate expect continu trade
posit strength exist immunolog oncolog asset expand
indic opportun view re-pric compani stock least top
rang larg biotech compani rang peer intern pharmaceut
price target base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl compar larg biopharmaceut compani price sale multipl
larg cap peer compani stock discount cash flow dcf appli peer ep
revenu multipl use averag larg cap larg molecul therapeut compani
midterm growth tail risk averag consensu
ep multipl appli current ep estim give valu
use revenu multipl similar compani consensu sale
appli revenu estim give valu lastli dcf
valuat given wacc termin cash flow growth rate begin
humira biosimilar entri give present valu averag three method
current price target
risk view outlook valuat includ major chang price
outlook reimburs coverag label competit posit humira compani
main product risk includ commerci develop disappoint compani
follow-on program inflammatori diseas imbruvica venclexta expand
hematolog malign well competit posit compani next-
gener hcv therapi also compani remain highli lever commit grow
dividend reduct forecast ebitda due neg busi trend would place
compani capit alloc strategi dividend growth risk opportun upsid
expect includ stronger-than-expect price volum share humira
emerg tangibl demand underappreci element compani early-to-
mid stage pipelin asset potenti label expans opportun late stage opportun
non-gaap cost good sold
interest expens
abbvi guidanc
late stage pipelin program includ
late stage pipelin program exclud
bispecif mab i/o rova-t non-rova-t
base current
valu base
price sale
multipl peer
sec gov compani websit present svbl analysi
phase ii data
phase data
phase ii data earli
phase ii data
phase ii data
phase ii data
phase ii data
phase data
phase data
phase ii data
phase ii data
phase ii data
bla file accept
decis
decis phase
phase data late
phase data
phase data
phase data
phase data
phase data
phase data
phase data
brand chemic name
type event
event trial detail
date known
specifi
up/down
svb leerink view
hmb uterin fibroid
nda file
svb leerink llc research compani file
primari complet
primari complet
sbla submiss expect
fda action nda launch expect
fda action bla launch expect
method price base current larg cap hc stock mid-term growth tail risk ep multipl appli ep
phase trial progress form ms
phase readout cd induct
regulatori submiss cgvhd
phase readout ra
phase readout ra
phase readout uc
phase readout ps
method present valu base price sale multipl peer larg cap biopharma stock rhhbi sni appli expect revenu
phase readout solid tumor
phase readout solid tumor
regulatori submiss ovarian breast
open label studi assess safety/toler
million
svb leerink llc research compani file
million
good sold
 total revenu
sg total revenu
svb leerink llc research compani file
analysi stock price svb leerink target
method price base current larg cap hc stock mid-term growth tail risk
ep multipl appli ep
svb leerink forma ep estim
method present valu base price sale multipl peer larg cap biopharma stock
rhhbi sni appli expect revenu
averag price sale larg cap biopharma multipl
impli market cap mm estimate sale
anticip share count mm
method leerink probabl adjust dcf adjust net wacc termin
current svb leerink dcf marketed/l stage program
sourc svb leerink llc estim compani file factset
